Turning Drug Resistance into a Therapeutic Opportunity in Sarcoma

Drug resistance remains one of the greatest challenges in cancer treatment. While many therapies initially succeed in slowing tumour growth, cancer cells can adapt over time, rendering previously effective treatments ineffective (1). For patients with advanced soft tissue sarcoma, the development of drug resistance can significantly limit available treatment options, particularly after failure of first-line therapies (2).

However, new research from scientists at the Institute of Cancer Research (ICR), London, has revealed an unexpected opportunity hidden within this problem (3). Their findings suggest that when sarcoma cells become resistant to one therapy, they may simultaneously develop new vulnerabilities that can be targeted with alternative treatments. This phenomenon, known as collateral sensitivity, could pave the way for more effective and personalised treatment strategies

Turning Resistance into an Advantage

Traditionally, cancer treatment has often involved administering a therapy until disease progression or drug resistance occurs, after which an alternative treatment is selected. While this approach can be effective, resistance-driven tumour adaptation may restrict future treatment choices and ultimately contribute to treatment failure and disease progression (1).

The ICR study challenges this model. Researchers found that as sarcoma cells evolved resistance to certain tyrosine kinase inhibitors (TKIs), they underwent molecular changes that created new therapeutic vulnerabilities, making them unexpectedly susceptible to alternative targeted therapies.

Rather than viewing resistance as a dead end, these findings suggest it may be possible to predict how cancer cells will evolve and exploit the weaknesses created by that evolution, potentially overcoming some of the treatment limitations associated with drug resistance. This concept forms the basis of the field known as evolutionary steering, where treatment strategies are designed not only to kill cancer cells but also to influence the direction of their adaptation.

What Changes Inside Resistant Cells?

Drug resistance is rarely caused by a single molecular change. As cancer cells adapt to therapeutic pressure, they can rewire intracellular signalling networks, alter kinase activity, and develop new dependencies on pathways that support survival and proliferation (1). In the ICR study, the evolution of resistance to tyrosine kinase inhibitors was associated with changes that created unexpected sensitivities to alternative targeted therapies (3).

Understanding these adaptations is an important area of ongoing research. Pathways such as PI3K/AKT and MAPK/ERK are frequently implicated in tumour growth, survival, and treatment resistance, while changes in cytokine signalling and the tumour microenvironment may further influence how cancer cells respond to therapy (1). By identifying the molecular alterations that accompany resistance, researchers may be able to predict emerging vulnerabilities and develop treatment strategies that exploit them. These adaptations may help explain the phenomenon of collateral sensitivity, whereby resistance to one therapy creates new vulnerabilities that can be targeted using alternative treatments.

Why Sarcomas Are Particularly Challenging

Sarcomas are among the most complex cancers to treat. More than 100 distinct sarcoma subtypes have been identified, each with unique genetic and biological characteristics (4). This diversity means that treatment responses can vary significantly between patients, making it difficult to predict which therapies will be most effective.

Targeted therapies such as TKIs have improved outcomes for some sarcoma patients, but resistance frequently develops (3). Cancer cells can activate alternative survival pathways, alter signalling networks, or modify interactions within their microenvironment to evade treatment effects.

Understanding these adaptive mechanisms is likely to be critical for developing more durable treatment strategies. The discovery of collateral sensitivity offers a promising new avenue for addressing this challenge by identifying vulnerabilities that emerge as tumours evolve.

Looking Ahead

The discovery of collateral sensitivity in sarcoma highlights a potentially crucial shift in how researchers think about drug resistance. Rather than simply attempting to prevent resistance from occurring, scientists may be able to anticipate and exploit the vulnerabilities that emerge as tumours evolve.

While further research is needed to translate these findings into clinical practice, the implications extend beyond sarcoma. Similar evolutionary principles may apply across multiple cancer types, creating opportunities for more adaptive and personalised treatment strategies. Ultimately, these efforts could help transform drug resistance from one of cancer treatment’s greatest challenges into a source of actionable therapeutic vulnerabilities.

As immune responses become a growing interest within research, access to validated and reliable reagents is increasingly important. Abbexa offers an extensive range of products designed to support research of the most specific cancer types.

1. Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., & Wang, L. (2025). Drug resistance in cancer: molecular mechanisms and emerging treatment strategies. Molecular biomedicine, 6(1), 111. https://doi.org/10.1186/s43556-025-00352-w
2. Sharma, S., Takyar, S., Manson, S. C., Powell, S., & Penel, N. (2013). Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. BMC cancer, 13, 385. https://doi.org/10.1186/1471-2407-13-385
3. Elms, M. L., Jenks, A. D., Chowdhury, A., Krasny, L., Chadha, M., Low, K., Harrison, P. T., Kerrison, W. G., Jones, R. L., & Huang, P. H. (2025). Exploiting collateral sensitivity in the evolution of resistance to tyrosine kinase inhibitors in soft tissue sarcomas. Communications biology, 8(1), 1185. https://doi.org/10.1038/s42003-025-08652-1
4. Sarcoma UK. (2026, March 24). What is sarcoma? | Sarcoma UK. https://sarcoma.org.uk/about-sarcoma/what-is-sarcoma/